How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,713 results for

Quetiapine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Neuroprotection after a first episode of mania: a randomized controlled maintenance trial comparing the effects of lithium and quetiapine on grey and white matter volume. (PubMed)

Neuroprotection after a first episode of mania: a randomized controlled maintenance trial comparing the effects of lithium and quetiapine on grey and white matter volume. Lithium and quetiapine are effective treatments for bipolar disorder, but their potential neuroprotective effects in humans remain unclear. A single blinded equivalence randomized controlled maintenance trial was conducted in a prospective cohort of first-episode mania (FEM) patients (n=26) to longitudinally compare (...) level 0.6 mmol l-1, n=20) or quetiapine (flexibly dosed up to 800 mg per day, n=19) monotherapy. At baseline, compared with healthy control subjects, patients with FEM showed reduced grey matter in the orbitofrontal cortex, anterior cingulate, inferior frontal gyrus and cerebellum. In addition, patients had reduced internal capsule white matter volume bilaterally (t1,66>3.20, P<0.01). Longitudinally, there was a significant treatment × time effect only in the white matter of the left internal

Full Text available with Trip Pro

2017 Translational psychiatry Controlled trial quality: uncertain

102. Quetiapine

Quetiapine USE OF QUETIAPINE IN PREGNANCY 0344 892 0909 USE OF QUETIAPINE IN PREGNANCY (Date of issue: March 2018 , Version: 3 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Quetiapine is an atypical antipsychotic used in the treatment (...) of schizophrenia, bipolar disorder, other psychoses and major depressive disorder. The considerable data regarding first trimester exposure to quetiapine does not suggest an overall increased risk of congenital malformation. More limited data does not support an association between quetiapine exposure and small for gestational age or preterm delivery. A single study has suggested an increased risk of spontaneous abortion, while no studies have investigated the risk of intrauterine death following in utero

2014 UK Teratology Information Service

103. Is use of quetiapine for sleep evidence-based?

Is use of quetiapine for sleep evidence-based? September - December 2010 79 © Tel.: 604 822•0700 Fax: 604 822•0701 E-mail: info@ti.ubc.ca www.ti.ubc.ca Mailing Address: Therapeutics Initiative The University of British Columbia Department of Anesthesiology, Pharmacology & Therapeutics 2176 Health Sciences Mall Vancouver, BC Canada V6T 1Z3 Is use of quetiapine for sleep evidence-based? The healthy subject study evaluated 14 males using a randomized, double-blind, crossover, placebo-controlled (...) , single-center design. Placebo or quetiapine at 25 and 100 mg doses were given on 3 consecutive nights with a 4-day washout period before crossover. Polysomnographic recordings were made nightly and subjective sleep-rating questionnaires completed each morn- ing. Both doses of quetiapine produced statisti- cally significant improvements in objective and subjective ratings of sleep, including total sleep time, sleep efficiency, sleep latency and duration of stage 2 sleep. The 100 mg dose increased peri

2011 Therapeutics Letter

104. Comparison of the effects of quetiapine extended-release and quetiapine immediate-release on cognitive performance, sedation and patient satisfaction in patients with schizophrenia: a randomised, double-blind, crossover study (eXtRa). (PubMed)

Comparison of the effects of quetiapine extended-release and quetiapine immediate-release on cognitive performance, sedation and patient satisfaction in patients with schizophrenia: a randomised, double-blind, crossover study (eXtRa). To assess daytime cognitive performance, sedation and treatment satisfaction in patients with schizophrenia receiving quetiapine extended release (XR) versus quetiapine immediate release (IR).Phase IV prospective, double-blind, crossover study (NCT01213836

2015 Schizophrenia Research Controlled trial quality: uncertain

105. Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2 × 2 factorial randomised trial. (PubMed)

Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2 × 2 factorial randomised trial. Depressive symptoms are a major cause of disability in bipolar disorder and there are few safe and effective treatments. The combination of lamotrigine plus quetiapine potentially offers improved outcomes for people with bipolar depression. We aimed to determine if combination therapy (...) with quetiapine plus lamotrigine leads to greater improvement in depressive symptoms over 12 weeks than quetiapine monotherapy plus lamotrigine placebo.In this double-blind, randomised, placebo-controlled, parallel group, 2 × 2 factorial trial (CEQUEL), patients with DSM-IV bipolar disorder I or II, who were aged 16 years or older, and required new treatment for a depressive episode, were enrolled from 27 sites in the UK. Patients were randomly assigned (1:1) by an adaptive minimisation algorithm

Full Text available with Trip Pro

2015 The Lancet. Psychiatry Controlled trial quality: predicted high

106. Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole (PubMed)

Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole Quantification of blood levels of antipsychotic drugs may be useful for managing medication therapy. This open-label, parallel-group study was performed to compare finger-stick-based capillary with corresponding venous plasma concentrations for risperidone, paliperidone, quetiapine, olanzapine, and aripiprazole and their major

Full Text available with Trip Pro

2016 Clinical pharmacology in drug development

107. Low-dose quetiapine complements stimulant response in attention deficit hyperactivity disorder and more (PubMed)

Low-dose quetiapine complements stimulant response in attention deficit hyperactivity disorder and more 28008352 2018 11 13 2045-1253 6 6 2016 Dec Therapeutic advances in psychopharmacology Ther Adv Psychopharmacol Low-dose quetiapine complements stimulant response in attention deficit hyperactivity disorder and more. 384-385 10.1177/2045125316672545 Naguy Ahmed A Al-Manara CAP Centre, Kuwait Centre for Mental Health, Jamal Abdul-Nassir Street, Shuwaikh, State of Kuwait. eng Journal Article

Full Text available with Trip Pro

2016 Therapeutic Advances in Psychopharmacology

108. Heavy Alcohol Drinking Associated Akathisia and Management with Quetiapine XR in Alcohol Dependent Patients (PubMed)

Heavy Alcohol Drinking Associated Akathisia and Management with Quetiapine XR in Alcohol Dependent Patients Heavy drinking contributes to involuntary body movements such as akathisia. Quetiapine has been shown to alleviate symptoms of akathisia; however, its efficacy in the alcohol dependent population is not well established. Thus, we aimed to identify efficacy of Quetiapine in treating akathisia in very heavy drinking alcohol dependent patients. 108 male and female heavy alcohol consuming (...) study participants received 13 weeks of Quetiapine XR. Drinking history (Timeline Followback, TLFB), depression (Montgomery-Asberg Depression Rating Scale, MADRS), and movement (Barnes Akathisia Scale, BARS) measures were collected at baseline (0 W), week 6 (6 W), and week 12 (12 W). The role of drinking, symptoms of depression, and efficacy of Quetiapine for treating akathisia were assessed. In patients with no symptoms of depression (low MADRS), Quetiapine treatment decreased symptoms of akathisia

Full Text available with Trip Pro

2016 Journal of addiction

109. Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation

Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02845453 Recruitment Status : Recruiting

2016 Clinical Trials

110. Pharmacokinetics of Quetiapine Across Pregnancy and Postpartum

Pharmacokinetics of Quetiapine Across Pregnancy and Postpartum Pharmacokinetics of Quetiapine Across Pregnancy and Postpartum - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Pharmacokinetics of Quetiapine (...) Across Pregnancy and Postpartum (Quetiapine) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02978534 Recruitment Status : Recruiting First Posted : December 1, 2016 Last Update Posted : December 1, 2016 See Sponsor

2016 Clinical Trials

111. Lithium Versus Quetiapine in Treatment Resistant Depression

Lithium Versus Quetiapine in Treatment Resistant Depression Lithium Versus Quetiapine in Treatment Resistant Depression - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Lithium Versus Quetiapine in Treatment (...) the clinical and cost effectiveness of lithium versus quetiapine when used as add-on therapies to antidepressant medication for patients with treatment resistant depression. The Lithium versus Quetiapine in Depression (LQD) study will assess patients over 12 months to establish which (if any) treatment is more likely to improve TRD over a long duration of time. Professor Anthony Cleare is the Chief Investigator and recruitment began in November 2016. Condition or disease Intervention/treatment Phase

2016 Clinical Trials

112. Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD

Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02720198 Recruitment Status : Completed First Posted : March 25, 2016 Last Update Posted : June 19, 2018 Sponsor: Duke

2016 Clinical Trials

113. Relative risks of cardiovascular disease in people prescribed olanzapine, risperidone and quetiapine. (PubMed)

Relative risks of cardiovascular disease in people prescribed olanzapine, risperidone and quetiapine. Antipsychotics may confer long term benefits and risks, including cardiovascular disease (CVD) risk. Several studies using routine clinical data have reported associations between antipsychotics and CVD but potential confounding factors and unclear classification of drug exposure limits their interpretation.We used data from The Health Improvement Network, a large UK primary care database (...) to determine relative risks of (CVD) comparing similar groups of people only prescribed olanzapine versus either risperidone or quetiapine. We included participants over 18 between 1995 and 2011. To assess confounding factors we created propensity scores for being prescribed each antipsychotic. We used propensity score matching and Poisson regression to calculate the CVD incidence rate ratios for olanzapine versus the other two drugs.We identified 18,319 people who received a single antipsychotic during

Full Text available with Trip Pro

2016 Schizophrenia Research

114. Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth. (PubMed)

Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth. To assess activating and tranquilizing effects of second-generation antipsychotics (SGAs) in youth.As part of the naturalistic inception cohort study, "Second-generation Antipsychotic Treatment Indication, Effectiveness and Tolerability in Youth (SATIETY)," subjective ratings of activating and tranquilizing symptoms were obtained monthly for 3 months from (...) antipsychotic-naïve youth initiating SGAs using the Treatment Emergent Symptoms Scale (TESS). Discontinuation rates, and TESS-reported symptom rates, and severity were related to clinical and treatment parameters. Two compound measures of TESS were defined: presence of any daytime activating (ACTIVATION+) and sedating symptoms (SEDATION+).In 327 antipsychotic-naïve youth originally initiating the four studied SGAs, discontinuation due to sedation was marginally highest with quetiapine (13.0%) followed

Full Text available with Trip Pro

2016 Journal of Child and Adolescent Psychopharmacology

115. Quetiapine use in adults in the community: a population-based study in Alberta, Canada. (PubMed)

Quetiapine use in adults in the community: a population-based study in Alberta, Canada. The objective of this study was to evaluate trends in prescribing of the second-generation antipsychotic medication quetiapine to adults in the province of Alberta from 2008 to 2013 through examination of dispensed prescriptions, and diagnoses associated with users of quetiapine in 2013.We analysed administrative data from Alberta Health; the Alberta Pharmaceutical Information Network (PIN) Dispenses health (...) data set, the Practitioner Payments (Fee-For-Service claims) health data set and the Population Registry health data set. These data sets allowed us to identify discrete quetiapine recipients for each calendar year from 2008 to 2013. To evaluate diagnoses associated with users of quetiapine, we evaluated diagnostic codes used by physicians in billings claims in 2013.Quetiapine use increased over the 6-year time period studied. In 2008, there were 16,087 unique quetiapine recipients in Alberta (7.2

Full Text available with Trip Pro

2016 BMJ open

116. Quetiapine-Induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone (PubMed)

Quetiapine-Induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) can be induced by various conditions, including malignant neoplasms, infections, central nervous system disorders, and numerous drugs. We here report a case of a 65-year-old female patient, treated with quetiapine for schizophrenia, who presented with generalized tonic-clonic seizures and was finally diagnosed with quetiapine-induced SIADH (...) . Quetiapine-associated hyponatremia is extremely uncommon and only a few, relevant reports can be found in the literature. This case underlines the fact that patients on antipsychotic medication and more specifically on quetiapine should be closely monitored and routinely tested for electrolyte disorders.

Full Text available with Trip Pro

2016 Case reports in psychiatry

117. Quetiapine

Quetiapine Quetiapine Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Quetiapine Quetiapine Aka: Quetiapine , Seroquel From Related (...) search on the term "Quetiapine." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Cost: Medications quetiapine (on 5/17/2017 at ) QUETIAPINE ER 150 MG TABLET Generic $10.87 each QUETIAPINE ER 200 MG TABLET Generic $11.65 each QUETIAPINE ER 300 MG TABLET Generic $15.35 each QUETIAPINE ER 400 MG TABLET Generic $17.19 each QUETIAPINE ER 50 MG TABLET Generic $6.02 each QUETIAPINE FUMARATE 100 MG TAB Generic $0.10 each QUETIAPINE

2018 FP Notebook

118. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. (PubMed)

Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. Some studies have indicated the efficacy of quetiapine in the treatment of generalized anxiety disorder (GAD).The purpose of this study was to systematically review the efficacy, acceptability, and tolerability of quetiapine in adult patients with GAD.The SCOPUS, MEDLINE, CINAHL, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov (...) databases were searched in April 2015. All randomized controlled trials (RCTs) of GAD were considered to be included in this meta-analysis. All RCTs of quetiapine in GAD patients providing endpoint outcomes relevant to severity of anxiety, response rate, remission rate, overall discontinuation rate, or discontinuation rate due to adverse events were included. The version reports from suitable clinical studies were explored, and the important data were extracted. Measurement for efficacy outcomes

Full Text available with Trip Pro

2016 Drug design, development and therapy

119. Evaluation of the use of low-dose quetiapine and the risk of metabolic consequences: A retrospective review (PubMed)

Evaluation of the use of low-dose quetiapine and the risk of metabolic consequences: A retrospective review Quetiapine fumarate is an atypical antipsychotic approved for the treatment of schizophrenia, major depressive disorder, and bipolar disorder. Due to the sedative effects observed at low doses, prescribers use quetiapine to aid patients with sleep disturbances. Current evidence has established that quetiapine can cause negative changes in metabolic parameters, but it is unknown (...) if these consequences also occur at low doses. Due to the use of quetiapine for sleep, the purpose of this study is to identify if metabolic effects are also a risk with the use of low-dose quetiapine.Eligible subjects were identified through the Veterans Affairs electronic medical records as having an active prescription for quetiapine from June 30, 2012, through September 1, 2013. Subjects were then evaluated using inclusion and exclusion criteria for determination of study entrance. Descriptive statistics and t

Full Text available with Trip Pro

2016 The Mental Health Clinician

120. Freeze Dried Quetiapine-Nicotinamide Binary Solid Dispersions: A New Strategy for Improving Physicochemical Properties and Ex Vivo Diffusion (PubMed)

Freeze Dried Quetiapine-Nicotinamide Binary Solid Dispersions: A New Strategy for Improving Physicochemical Properties and Ex Vivo Diffusion Improving the physicochemical properties and oral bioavailability of quetiapine fumarate (QF) enabling enhanced antipsychotic attributes are the main aims of this research. The freeze dried solid dispersion strategy was adopted using nicotinamide (NIC) as highly soluble coformer. The prepared dispersions were characterized using scanning electron (...) microscopy (SEM) differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR), and X-ray diffraction (XRD). Static disc intrinsic dissolution rate and ex vivo diffusion through intestinal tissues were conducted and compared to pure quetiapine fumarate. The results demonstrated a highly soluble coamorphous system formed between quetiapine fumarate and nicotinamide at 1 : 3 molar ratio through H-bonding interactions. The results showed >14-fold increase in solubility of QF from

Full Text available with Trip Pro

2016 Journal of pharmaceutics

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>